MADISON, Wis.--(BUSINESS WIRE)--TomoTherapy Incorporated (NASDAQ:TTPY) is entering the proton therapy business through a collaboration with scientists at California’s Lawrence Livermore National Laboratory (LLNL). The makers of the TomoTherapy® Hi-Art® treatment system have agreed to fund continued development of a revolutionary accelerator that it expects will form the basis of a compact, low-cost proton therapy system. The system, which uses dielectric wall accelerator (DWA) technology, is the result of defense-related research and, with further development, has the potential to bring proton therapy into the medical mainstream. LLNL has worked to develop the technology with the UC Davis Cancer Center, which helped finance the early development of the DWA as a proton accelerator for cancer treatment.
